NZ505905A - Metallocorrinoids as biologically compatible carriers of nitric oxide (NO) - Google Patents
Metallocorrinoids as biologically compatible carriers of nitric oxide (NO)Info
- Publication number
- NZ505905A NZ505905A NZ505905A NZ50590598A NZ505905A NZ 505905 A NZ505905 A NZ 505905A NZ 505905 A NZ505905 A NZ 505905A NZ 50590598 A NZ50590598 A NZ 50590598A NZ 505905 A NZ505905 A NZ 505905A
- Authority
- NZ
- New Zealand
- Prior art keywords
- group
- metallocorrinoid
- pharmacological agent
- complex
- carbon atoms
- Prior art date
Links
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 title claims abstract description 136
- 239000000969 carrier Substances 0.000 title description 3
- 239000002831 pharmacologic agent Substances 0.000 claims abstract description 47
- 238000000034 method Methods 0.000 claims abstract description 24
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 20
- 150000001875 compounds Chemical class 0.000 claims abstract description 15
- 239000002904 solvent Substances 0.000 claims abstract description 11
- 229910052742 iron Inorganic materials 0.000 claims abstract description 10
- 125000005842 heteroatom Chemical group 0.000 claims abstract description 9
- 229910052759 nickel Inorganic materials 0.000 claims abstract description 9
- 229910052748 manganese Inorganic materials 0.000 claims abstract description 8
- 230000004962 physiological condition Effects 0.000 claims abstract description 8
- 125000001931 aliphatic group Chemical group 0.000 claims abstract description 7
- 125000003118 aryl group Chemical group 0.000 claims abstract description 7
- 229910052804 chromium Inorganic materials 0.000 claims abstract description 7
- 229910052802 copper Inorganic materials 0.000 claims abstract description 7
- 239000012038 nucleophile Substances 0.000 claims abstract description 7
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 7
- 229910052706 scandium Inorganic materials 0.000 claims abstract description 6
- 229910052719 titanium Inorganic materials 0.000 claims abstract description 6
- 229910052720 vanadium Inorganic materials 0.000 claims abstract description 6
- 239000002253 acid Substances 0.000 claims abstract 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 18
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
- 150000001408 amides Chemical class 0.000 claims description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 6
- 229910019142 PO4 Inorganic materials 0.000 claims description 5
- -1 cyano, hydroxyl Chemical group 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000010452 phosphate Substances 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052723 transition metal Inorganic materials 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 229910017052 cobalt Inorganic materials 0.000 claims description 3
- 239000010941 cobalt Substances 0.000 claims description 3
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical group [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 230000000144 pharmacologic effect Effects 0.000 claims description 3
- 150000003624 transition metals Chemical class 0.000 claims description 3
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 229910021645 metal ion Inorganic materials 0.000 abstract 2
- YOZNUFWCRFCGIH-BYFNXCQMSA-L hydroxocobalamin Chemical compound O[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O YOZNUFWCRFCGIH-BYFNXCQMSA-L 0.000 description 20
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 14
- 238000001727 in vivo Methods 0.000 description 13
- 235000004867 hydroxocobalamin Nutrition 0.000 description 10
- 239000011704 hydroxocobalamin Substances 0.000 description 10
- 229960001103 hydroxocobalamin Drugs 0.000 description 10
- WUPRCGRRQUZFAB-DEGKJRJSSA-N corrin Chemical group N1C2CC\C1=C\C(CC/1)=N\C\1=C/C(CC\1)=N/C/1=C\C1=NC2CC1 WUPRCGRRQUZFAB-DEGKJRJSSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 235000011468 Albizia julibrissin Nutrition 0.000 description 5
- 241001070944 Mimosa Species 0.000 description 5
- 229930003779 Vitamin B12 Natural products 0.000 description 5
- 150000001867 cobalamins Chemical class 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 235000019163 vitamin B12 Nutrition 0.000 description 5
- 239000011715 vitamin B12 Substances 0.000 description 5
- 230000029663 wound healing Effects 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 4
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 4
- 229940127089 cytotoxic agent Drugs 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 159000000021 acetate salts Chemical class 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 229940010007 cobalamins Drugs 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000003712 lysosome Anatomy 0.000 description 3
- 230000001868 lysosomic effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 230000000269 nucleophilic effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000002411 adverse Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 235000000639 cyanocobalamin Nutrition 0.000 description 2
- 239000011666 cyanocobalamin Substances 0.000 description 2
- 229960002104 cyanocobalamin Drugs 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000001163 endosome Anatomy 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000002840 nitric oxide donor Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 102000011848 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase Human genes 0.000 description 1
- 108010075604 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- YOCIQNIEQYCORH-UHFFFAOYSA-M chembl2028361 Chemical compound [Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=CC=C1 YOCIQNIEQYCORH-UHFFFAOYSA-M 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- UUWYBLVKLIHDAU-UHFFFAOYSA-K cobalt(3+);[5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] 1-[3-[2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7,12,17-tetrahydro-1h-corrin-21-id-3-yl]propanoylamino]propan-2 Chemical compound [Co+3].[O-]N=O.OCC1OC(N2C3=CC(C)=C(C)C=C3N=C2)C(O)C1OP([O-])(=O)OC(C)CNC(=O)CCC1(C)C(CC(N)=O)C2[N-]\C1=C(C)/C(C(C\1(C)C)CCC(N)=O)=N/C/1=C\C(C(C/1(CC(N)=O)C)CCC(N)=O)=N\C\1=C(C)/C1=NC2(C)C(C)(CC(N)=O)C1CCC(N)=O UUWYBLVKLIHDAU-UHFFFAOYSA-K 0.000 description 1
- WBSXYJYELWQLCJ-UHFFFAOYSA-K cobalt(3+);[5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] 1-[3-[2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7,12,17-tetrahydro-1h-corrin-21-id-3-yl]propanoylamino]propan-2 Chemical compound O.[OH-].[Co+3].OCC1OC(N2C3=CC(C)=C(C)C=C3N=C2)C(O)C1OP([O-])(=O)OC(C)CNC(=O)CCC1(C)C(CC(N)=O)C2[N-]\C1=C(C)/C(C(C\1(C)C)CCC(N)=O)=N/C/1=C\C(C(C/1(CC(N)=O)C)CCC(N)=O)=N\C\1=C(C)/C1=NC2(C)C(C)(CC(N)=O)C1CCC(N)=O WBSXYJYELWQLCJ-UHFFFAOYSA-K 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 description 1
- 235000007672 methylcobalamin Nutrition 0.000 description 1
- 239000011585 methylcobalamin Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 239000001301 oxygen Chemical group 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229910052698 phosphorus Chemical group 0.000 description 1
- 239000011574 phosphorus Chemical group 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/000,581 US5936082A (en) | 1997-12-30 | 1997-12-30 | Metallocorrinoids as biologically compatible carriers of pharmacological agents |
| PCT/US1998/027857 WO1999033833A1 (en) | 1997-12-30 | 1998-12-30 | Metallocorrinoids as biologically compatible carriers of pharmacological agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ505905A true NZ505905A (en) | 2003-05-30 |
Family
ID=21692125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ505905A NZ505905A (en) | 1997-12-30 | 1998-12-30 | Metallocorrinoids as biologically compatible carriers of nitric oxide (NO) |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US5936082A (OSRAM) |
| EP (1) | EP1066292B1 (OSRAM) |
| JP (1) | JP2001527077A (OSRAM) |
| CN (1) | CN1142934C (OSRAM) |
| AU (1) | AU754303B2 (OSRAM) |
| DE (1) | DE69812721T2 (OSRAM) |
| DK (1) | DK1066292T3 (OSRAM) |
| IN (1) | IN192148B (OSRAM) |
| NO (1) | NO316688B1 (OSRAM) |
| NZ (1) | NZ505905A (OSRAM) |
| WO (1) | WO1999033833A1 (OSRAM) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5739313A (en) * | 1995-11-13 | 1998-04-14 | Regents Of The University Of Minnesota | Radionuclide labeling of vitamin B12 and coenzymes thereof |
| US6806363B1 (en) * | 1999-04-16 | 2004-10-19 | Mayo Foundation For Medical Education & Research | Cobalamin conjugates useful as antitumor agents |
| EP1231942A1 (en) * | 1999-10-15 | 2002-08-21 | Mayo Foundation For Medical Education And Research | Cobalamin conjugates useful as imaging agents and as antitumor agents |
| JP2003531105A (ja) | 1999-10-15 | 2003-10-21 | メイオウ・フアウンデーシヨン・フオー・メデイカル・エジユケイシヨン・アンド・リサーチ | 造影剤および治療薬として有用なコバラミン結合体 |
| US7591995B2 (en) * | 1999-10-15 | 2009-09-22 | Mayo Foundation For Medical Education And Research | Cobalamin conjugates useful as imaging and therapeutic agents |
| TWI228512B (en) * | 2000-10-25 | 2005-03-01 | Mayo Foundation | Transcobalamin binding conjugates useful for treating abnormal cellular proliferation |
| US6752986B2 (en) * | 2001-05-24 | 2004-06-22 | The Cleveland Clinic Foundation | Composition and methods for affecting metallocorrinoid uptake |
| JP2005508332A (ja) * | 2001-09-28 | 2005-03-31 | メイオウ・フアウンデーシヨン・フオー・メデイカル・エジユケイシヨン・アンド・リサーチ | 薬剤を送達するための、輸送タンパク質とコンジュゲートコバラミンとの同時投与 |
| CA2516453A1 (en) * | 2003-02-20 | 2004-09-02 | The Cleveland Clinic Foundation | Composition and methods for inhibiting cell survival |
| WO2005105171A1 (en) * | 2004-04-29 | 2005-11-10 | Cube Medical A/S | A balloon for use in angioplasty with an outer layer of nanofibers |
| MX2007001348A (es) * | 2004-08-02 | 2008-03-11 | Bebaas Inc | Composiciones de vitamina b12. |
| CN101222853B (zh) * | 2005-05-17 | 2012-07-18 | 卡吉尔公司 | 粒状卵磷脂、粒状溶血卵磷脂、它们的生产方法和包含它们的组合物 |
| US20130131007A1 (en) | 2005-09-07 | 2013-05-23 | Bebaas, Inc. | Vitamin b12 compositions |
| US20070178141A1 (en) * | 2005-09-07 | 2007-08-02 | Bebaas, Inc. | Vitamin B12 compositions |
| EP1979487A4 (en) * | 2006-01-26 | 2010-05-05 | Bebaas Inc | COBALAMINE COMPOSITIONS FOR THE TREATMENT OF CANCER |
| KR102241407B1 (ko) * | 2019-08-22 | 2021-04-16 | 재단법인대구경북과학기술원 | 광분해성 코발트 나이트로실 착물 및 이를 포함하는 일산화질소 전달체 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0210014A (ja) * | 1988-06-28 | 1990-01-12 | Matsushita Seiko Co Ltd | ごみ処理装置 |
| WO1990010014A1 (fr) * | 1989-02-28 | 1990-09-07 | Teijin Limited | Nouveau derive de vitamine b12, sa production et son application |
| WO1995031204A1 (en) * | 1994-05-17 | 1995-11-23 | Research Corporation Technologies, Inc. | Cobalamins as nitric oxide sequestrants |
-
1997
- 1997-12-30 US US09/000,581 patent/US5936082A/en not_active Expired - Lifetime
-
1998
- 1998-12-30 DE DE69812721T patent/DE69812721T2/de not_active Expired - Lifetime
- 1998-12-30 EP EP98965035A patent/EP1066292B1/en not_active Expired - Lifetime
- 1998-12-30 WO PCT/US1998/027857 patent/WO1999033833A1/en not_active Ceased
- 1998-12-30 CN CNB988138220A patent/CN1142934C/zh not_active Expired - Fee Related
- 1998-12-30 DK DK98965035T patent/DK1066292T3/da active
- 1998-12-30 AU AU20233/99A patent/AU754303B2/en not_active Ceased
- 1998-12-30 NZ NZ505905A patent/NZ505905A/en not_active IP Right Cessation
- 1998-12-30 JP JP2000526513A patent/JP2001527077A/ja not_active Withdrawn
-
2000
- 2000-06-29 NO NO20003411A patent/NO316688B1/no not_active IP Right Cessation
- 2000-07-26 IN IN220MU2000 patent/IN192148B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU754303B2 (en) | 2002-11-14 |
| DE69812721T2 (de) | 2004-01-15 |
| CN1142934C (zh) | 2004-03-24 |
| AU2023399A (en) | 1999-07-19 |
| NO316688B1 (no) | 2004-04-05 |
| DK1066292T3 (da) | 2003-07-14 |
| JP2001527077A (ja) | 2001-12-25 |
| NO20003411D0 (no) | 2000-06-29 |
| EP1066292A1 (en) | 2001-01-10 |
| EP1066292A4 (en) | 2001-08-16 |
| CN1284958A (zh) | 2001-02-21 |
| US5936082A (en) | 1999-08-10 |
| WO1999033833A1 (en) | 1999-07-08 |
| HK1034257A1 (en) | 2001-10-19 |
| NO20003411L (no) | 2000-08-14 |
| EP1066292B1 (en) | 2003-03-26 |
| DE69812721D1 (de) | 2003-04-30 |
| IN192148B (OSRAM) | 2004-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1066292B1 (en) | Metallocorrinoids as biologically compatible carriers of pharmacological agents | |
| Yan et al. | Metal-containing and related polymers for biomedical applications | |
| NO332539B1 (no) | Anvendelse av en blanding av et vannloselig anti-tumor legemiddel og et platina legemiddel for fremstilling av et legemiddelpreparat for behandling av sykdom | |
| AU2008260203B2 (en) | Metal complexes incorporated within biodegradable nanoparticles and their use | |
| WO2000012512A1 (en) | Porphyrin derivatives, their use in photodynamic therapy and medical devices containing them | |
| EP1322654A1 (en) | Platinum complexes as antitumor agents | |
| CN108503726B (zh) | 一种酞菁-壳寡糖偶联物及其制备方法与应用 | |
| EP1534347A2 (en) | Conjugates of n-hydroxypropymethacrylamide-methacrylate copolymer with nuclide activation agent and/or anti-cancer compounds | |
| CN111053911A (zh) | 还原响应型交联剂及其交联羟基药物分子的制备及应用 | |
| Ol'shevskaya et al. | Boronated protohaemins: synthesis and in vivo antitumour efficacy | |
| CN112656960A (zh) | 一种线粒体调控型铁基磁性配位聚合物纳米粒及其制备方法和应用 | |
| CN117717562B (zh) | 一种联合吉西他滨治疗胰腺癌的纳米载药复合物及其制备方法 | |
| Pearce et al. | A Potential Antidote for both Azide and Cyanide Poisonings | |
| CN112266396B (zh) | 一种基于生物正交化学的整合型前药、制备方法及其医药用途 | |
| ES2893849T3 (es) | Complejo de oro(III), conjugado del complejo de oro(III), composición farmacéutica que comprende el complejo de oro(III) y usos y un proceso de preparación del complejo de oro(III) | |
| Král et al. | A non-ionic water-soluble pentaphyrin derivative. Synthesis and cytotoxicity | |
| EP1704870A1 (en) | Use of iron compounds as radiosensitizers | |
| HK1034257B (en) | Metallocorrinoids as biologically compatible carriers of pharmacological agents | |
| CN116712543B (zh) | 一种光响应的离子对组合物及其抗癌应用 | |
| Sessler | OxaliTEX-Pt (IV): A case study in medicinal inorganic chemical lead development. | |
| Papakyriakou et al. | Structural studies on metallobleomycins: The interaction of Pt (II) and Pd (II) with bleomycin | |
| Klosowski | Gold (III)-dithiocarbamato complexes: antibacterial properties and encapsulation studies into Metal-Organic Frameworks (MOFs) for drug delivery | |
| WO1998014456A1 (en) | Method for treating cyanide poisoning | |
| PL245357B1 (pl) | Pochodna cisplatyny o cytotoksyczności kontrolowanej światłem UV/VIS, sposób jej wytwarzania oraz zastosowanie w terapii antynowotworowej | |
| Tavakolinia | Synthesis and study of dinuclear cobalt (III)-platinum (II) complexes as potential anti-cancer pro-drugs. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| EXPY | Patent expired |